ATE270111T1 - Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren - Google Patents

Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren

Info

Publication number
ATE270111T1
ATE270111T1 AT94911691T AT94911691T ATE270111T1 AT E270111 T1 ATE270111 T1 AT E270111T1 AT 94911691 T AT94911691 T AT 94911691T AT 94911691 T AT94911691 T AT 94911691T AT E270111 T1 ATE270111 T1 AT E270111T1
Authority
AT
Austria
Prior art keywords
biologically
composition
toxicity
reducing
biologically active
Prior art date
Application number
AT94911691T
Other languages
English (en)
Inventor
Lawrence Tamarkin
Giulio Franco Paciotti
Original Assignee
Cytimmune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytimmune Sciences Inc filed Critical Cytimmune Sciences Inc
Application granted granted Critical
Publication of ATE270111T1 publication Critical patent/ATE270111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94911691T 1993-03-18 1994-03-18 Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren ATE270111T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3338593A 1993-03-18 1993-03-18
PCT/US1994/003177 WO1994021288A1 (en) 1993-03-18 1994-03-18 Composition and method for reducing toxicity of biologically-active factors

Publications (1)

Publication Number Publication Date
ATE270111T1 true ATE270111T1 (de) 2004-07-15

Family

ID=21870121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911691T ATE270111T1 (de) 1993-03-18 1994-03-18 Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren

Country Status (7)

Country Link
EP (1) EP0690722B1 (de)
JP (1) JP3880063B2 (de)
AT (1) ATE270111T1 (de)
AU (1) AU6414994A (de)
CA (1) CA2158475C (de)
DE (1) DE69433870T2 (de)
WO (1) WO1994021288A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
AU2003231660B2 (en) * 1997-11-10 2006-05-18 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
AU757357B2 (en) * 1997-11-10 2003-02-20 Cytimmune Sciences, Inc. Methods and compositions for enhancing immune response and for the production of in vitro mabs
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
ATE320270T1 (de) * 1997-11-10 2006-04-15 Cytimmune Sciences Inc Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1146906B1 (de) 1999-02-05 2011-07-06 Alk-Abelló A/S Mukosales verabreichungssytem
FR2792639B1 (fr) 1999-04-26 2003-06-06 Neovacs Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
AU2002259107B2 (en) * 2001-04-30 2006-10-26 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
WO2002094294A1 (en) 2001-05-25 2002-11-28 Gorm Danscher A method of implanting heavy metal such as nobel metal, e.g. gold, and metal for use in implantation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10235602B4 (de) * 2002-08-02 2010-01-14 Universität Duisburg-Essen Metallcluster-Nanoverbindungen zur Behandlung von Tumorerkrankungen
EP1635850B1 (de) * 2003-06-20 2008-08-13 Johnson & Johnson Medical Ltd. Antimikrobielle zusammensetzung enthaltend silber
CN100457775C (zh) 2003-08-08 2009-02-04 普洛图斯科学株式会社 具有脑定位活性的多肽及其用途
WO2006013650A1 (ja) * 2004-08-06 2006-02-09 Tissue Targeting Japan Inc. 金属コロイド粒子を含有する脳神経細胞内移行用キャリア
AU2004311630A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
GB0500898D0 (en) * 2005-01-18 2005-02-23 Smith & Nephew Gold-protein coagulation
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
RU2519645C2 (ru) 2008-05-14 2014-06-20 Эгрикалчер Виктория Сервисиз Пти Лтд Применение ангиогенина или агонистов ангиогенина для лечения заболеваний и нарушений
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
HK1254839A1 (zh) * 2015-08-13 2019-07-26 Northeastern University 用於联合的癌症的放射疗法和免疫疗法的生物材料
JP6635319B1 (ja) * 2018-07-31 2020-01-22 株式会社東洋厚生製薬所 ナチュラルキラー細胞活性化剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269912A (en) * 1963-04-08 1966-08-30 Boehringer & Soehne Gmbh Aluminum oxide depot vaccines
FR2334366A2 (fr) * 1975-12-10 1977-07-08 Anvar Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine
JPS62162963A (ja) * 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド

Also Published As

Publication number Publication date
JP3880063B2 (ja) 2007-02-14
EP0690722A1 (de) 1996-01-10
DE69433870T2 (de) 2005-06-30
AU6414994A (en) 1994-10-11
WO1994021288A1 (en) 1994-09-29
EP0690722A4 (de) 1997-08-06
EP0690722B1 (de) 2004-06-30
CA2158475A1 (en) 1994-09-29
DE69433870D1 (de) 2004-08-05
JPH08511236A (ja) 1996-11-26
CA2158475C (en) 2009-06-02

Similar Documents

Publication Publication Date Title
DE69433870D1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
DK127788D0 (da) Farmaceutiske praeparater til anvendelse til behandling eller forebyggelse af sygdomme i mavetarmkanalen
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE69805983D1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
DE69535976D1 (de) Heilung von Wunden oder fibrotischen Krankheiten unter Verwendung von wenigstens einem Agens gegen einen Wachstumsfaktor
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
JO1619B1 (en) Contrast media
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69719095D1 (de) Gallensauersälze mit physiologisch aktiven metalle und ihre verwendung zur therapeutischen behandlung
ATE175349T1 (de) Verwendung von etofibrat und pharmazeutische zusammensetzungen, enthaltend etofibrat, zur behandlung der diabetischen angio- und retinopathie
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0690722

Country of ref document: EP